ID   425
AC   CVCL_LB64
SY   MAb425; mAb 425; mAb425; EMD55900; EMD 55900
DR   ATCC; HB-9629
DR   Wikidata; Q54603012
RX   Patent=US5470571;
RX   PubMed=2434025;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9629.
CC   Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized matuzumab (EMD 72000) therapeutic antibody. It was developed by Merck Serono for the treatment of a number of cancer types. It failed phase II clinical trials.
CC   Monoclonal antibody isotype: IgG2a.
CC   Monoclonal antibody target: UniProtKB; P00533; Human EGFR.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 22-08-17; Last updated: 21-03-23; Version: 5
//
RX   Patent=US5470571;
RA   Herlyn M., Rodeck U.;
RT   "Method of treating human EGF receptor-expressing gliomas using
RT   radiolabeled EGF receptor-specific MAB 425.";
RL   Patent number US5470571, 28-Nov-1995.
//
RX   PubMed=2434025; DOI=10.1016/0003-9861(87)90062-2;
RA   Murthy U., Basu A., Rodeck U., Herlyn M., Ross A.H., Das M.;
RT   "Binding of an antagonistic monoclonal antibody to an intact and
RT   fragmented EGF-receptor polypeptide.";
RL   Arch. Biochem. Biophys. 252:549-560(1987).
//